GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LIM:GILD) » Definitions » Investments And Advances

Gilead Sciences (LIM:GILD) Investments And Advances : $0 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gilead Sciences Investments And Advances?

Gilead Sciences's Investments And Advances for the quarter that ended in Sep. 2024 was $0 Mil.

Gilead Sciences's annual Investments And Advances declined from Dec. 2021 ($1,309 Mil) to Dec. 2022 ($1,245 Mil) and declined from Dec. 2022 ($1,245 Mil) to Dec. 2023 ($1,163 Mil).


Gilead Sciences Investments And Advances Historical Data

The historical data trend for Gilead Sciences's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Investments And Advances Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,488.00 502.00 1,309.00 1,245.00 1,163.00

Gilead Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,156.00 1,163.00 - - -

Gilead Sciences Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Gilead Sciences Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).